Open AccessSuccessful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
Author(s) -
Alexia Rouland,
Benjamin Bouillet,
Pauline Legris,
Isabelle Simoneau,
JeanMichel Petit,
Bruno Vergès
Publication year - 2021
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1179-1438
DOI - 10.2147/cpaa.s278978
Subject(s) - nesidioblastosis , pasireotide , hypoglycemia , medicine , hyperinsulinemic hypoglycemia , diazoxide , insulinoma , endocrinology , somatostatin , octreotide , insulin , gastroenterology , acromegaly , hormone , growth hormone
Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypoglycemia.